EGFR and glioblastoma: Based on hypothesizing that inhibition of both EGFR and Ras would improve the survival time of patients with recurrent GBM, a phase II trial in 2013 was launched but did not reach the effective hypothesis H0 (30% increase in overall survival time compared with historical controls) (38).